Reuters
20 Nov 2026, 12:49 UTC · 34m ago
Erasca's pill shrinks hard-to-treat pancreatic and lung tumors in early-stage trial
Impact · against what's priced in
Erasca shows positive early-stage clinical activity in difficult-to-treat pancreatic and lung cancers. This provides a tangible proof-of-concept for its pipeline, serving as a positive catalyst for valuation.
- ERCA+0.40
No priced-in read yet
- In context
The pill's ability to shrink tumors in hard-to-treat pancreatic and lung cancers provides critical early-stage validation for the drug's efficacy.
Read from the article alone
- Actual





